MiNK Therapeutics CEO Jennifer Buell
November 10, 2022 09:37 AM EST
R&D
Coronavirus

In wan­ing Covid mar­ket, MiNK un­veils da­ta on nat­ur­al killer T cell ther­a­py for ARDS, pend­ing con­tract with DARPA

Lei Lei Wu

News Reporter

In an SITC poster, Agenus’ spin­out MiNK Ther­a­peu­tics dropped the re­sults of a Phase I/II study of its lead can­di­date, made from rare im­mune cells …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Phar­ma's wins and loss­es in Trump's sprawl­ing ex­ec­u­tive or­der on drug prices

US drugs re­ly heav­i­ly on in­gre­di­ents made over­seas, new re­port shows

Nether­lands pours $1.5B in­to biotech in pur­suit of glob­al lead­er­ship am­bi­tions

Eli Lil­ly re­ports first Phase 3 da­ta for oral GLP-1, post­ing a win in di­a­betes

Sanofi to pay $125M up­front for two im­munol­o­gy drugs from lit­tle-known biotech

sponsored

New York-based part­ner­ship sets the stan­dard for ex­pand­ing clin­i­cal tri­al ac­cess for un­der­served and di­verse ...

A service from the Financial Times